2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious

While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, there's no shortage of reasons to buy its stock. Still, there is a risk that could rain on the biotech's parade a bit over the next couple of years.Let's examine two reasons why the stock is worth buying, and one reason why it makes sense to be just a little bit cautious with an investment.Amgen is keen to launch a drug to give it some exposure to the anti-obesity drug gold rush that's going on right now. It has two disclosed programs, one of which is in phase 2 clinical trials, and the other of which is in phase 1.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool